
PGY-2 resident @BMCSouthIM @BMC_Brighton| Clinical instructor @BUmedicine | Former Research Fellow @mghcvrc @harvardmed |@alexandriamed alumni
Boston, MA
Joined February 2023
- Tweets180
- Following588
- Followers645
- Likes749
Publication 🚨
We compared semaglutide vs tirzepatide in over 5K matched pairs of adults with obesity and ASCVD without diabetes.
I would like to congratulate all the coauthors on their efforts!
Shoutout to my partner in crime @MohamedDomaa !
doi.org/10.1016/j.ahjo.2026.…
Can't wait to meet you all at #TCT2026 in San Diego. Come say hi and let's talk CTO PCI!
30 day outcomes, CTO vs non CTO PCI: sciencedirect.com/science/ar…
LVEF recovery after CTO PCI: hmpgloballearningnetwork.com…
1
19
699
publication 🚨
We compared GLP-1 RAs and SGLT2i, alone and in combination, for AF recurrence and cardiovascular outcomes after catheter ablation.
Proud of this work with an incredible team. @hrs_journal
#Cardiology #EPeeps #AFib #GLP1RA #CardioX
heartrhythmjournal.com/artic…
Grateful to be part of this with an incredible team. Thank you to all co-authors and a special thanks to @michaelmegalymd for his mentorship and guidance. @MyJSCAI #CTOPCI #CardioX
Among the criticisms of #CTO #PCI is the higher risk compared to regular PCI procedures. This perception stems from the procedure's higher complexity.
The unmeasured factor is that CTO PCI is usually performed by operators who can identify and treat possible complications faster and have the awareness to prevent problems or manage them.
Our study from the National Trinetix database @MyJSCAI, led by @AdhamGR97 and @MohamedDomaa, compared 30-day outcomes between CTO PCI and ELECTIVE (non-MI) non-CTO PCI, and also trended outcomes over three recent periods (2014-2017, 2018-2021, 2022-2025).
Our major findings are as follows
1-CTO PCI risk of pericardiocentesis was higher than non-CTO PCI (0.2% vs 0.09%) but remains very small at 0.2%
2-CABG after CTO PCI was higher than non-CTO PCI; we could not determine the cause, but it was mostly related to failure and the need for revascularization rather than complications.
Also, the trend of CABG after CTO PCI has been decreasing.
3-Finally, none of this led to adverse outcomes, as there was absolutely no difference in mortality between the two groups.
In the hands of experienced operators, CTO PCI can be safe and effective.
sciencedirect.com/science/ar…
#CardioX #ACCFIT
🚨 New paper out in CRM!
We examined early pericardial complications after LAAO and their long-term clinical outcomes.
🔗 doi.org/10.1016/j.carrev.202…
@CRMjournal @MohamedDomaa @jibran_ikram @AllanLKleinMD1 @AGoldsweig
#LAAO #Cardiology #CardioX #MedX
Check out our new editorial in Heart Rhythm on the OPTION trial subanalysis: LAAC vs oral anticoagulation after AF ablation, by stroke risk.
🔗 : heartrhythmjournal.com/artic…
@MohamedDomaa @AGoldsweig
#CardioX #ACCFIT
Full study 🔗: heartrhythmjournal.com/artic…
1
108
publication 🚨
In this review, we discuss GLP-1RAs' role beyond glucose-lowering agents, with a more focused approach towards their cardiometabolic-modifying effects.
Full paper 👇
journals.lww.com/cardiologyi…
#Cardiology #Med #GLP1RA #CardioTwitter
1
9
365
Honored to receive the Outstanding Internal Medicine Intern award this year. Grateful to my attendings, co-residents, and the entire team for making this year one to remember. On to PGY-2!
#MedTwitter #IMResidency #MedEd
🚨 New paper out in @AJCardiology!
We compared DOACs vs warfarin in LVAD recipients without AF in a large real-world propensity matched cohort.
Grateful to all co-authors and senior authors for their support 🙏
🔗 ajconline.org/article/S0002-…
#HeartFailure #LVAD #CardioTwitter
2
11
839
🚨 New paper out in @rheumjnl!
We examined TAVR outcomes in patients with rheumatoid arthritis and aortic stenosis
🔗 doi.org/10.1093/rheumatology…
#Rheumatology #TAVR #AorticStenosis #CardioTwitter #MedTwitter
Huge thank you to my partner in crime @MohamedDoma for his immense work on this, and to our senior authors @AGoldsweig and @islamelgendy83 for their invaluable guidance throughout. Grateful to all co-authors for their contributions 🙏 @AhmedMahmoud_MD @IuriFFelix
Excited to see our study on CTO PCI in cardiogenic shock published in CJC.
Sincere thanks to our senior authors, especially Dr.@MichaelMegalyMD , for his mentorship and support.
Honored to be part of this work
#CTO #PCI in cardiogenic shock, shall we even do it?
Our study led by @MohamedDomaa and @AdhamGR97 in the @CJCJournals investigated the long-term outcomes of patients who already had a diagnosis of cardiogenic shock and underwent CTO PCI in the same hospitalization.
While the in-hospital mortality is around 27% (which is way lower than the 40-50% cited mortality of cardiogenic shock), the long-term survival was even more impressive, with a 5-year survival of 60%.
We stipulate that the reason CTO PCI was performed was either that further revascularization was needed (e.g., inability to wean from mechanical circulatory support) or that the culprit of shock was NSTEMI with multiple CTOs (18% of our cohort)
Any other reason you would do CTO PCI in shock?
onlinecjc.ca/article/S0828-2…
Pleasured & honored to present our work at #ACC26 @ACCinTouch !
Wonderful experience as always in NOLA 🎷 🫀
My sincerest gratitude to all the co-authors for their efforts on this manuscript where we highlight how LAAO can be a significant alternative especially in patients susceptible to GI bleed.
Shoutout Dr.@AGoldsweig for his continuous support and efforts !
Please check out our most recent @pace_journal publication on the risk of recurrent GI bleeding in AF patients undergoing LAAO.🫀🩸
@DrDeese99 @MohamedDomaa
#AtrialFibrillation #LAAO #EPeeps #CardioTwitter
Excited to share our Editorial with the amazing @MichaelMegalyMD on the role of VBT in ISR and the role of vessel size. #cardiotwitter #MedTwitter
Link 🔗 sciencedirect.com/science/ar…
Original study 🔗 sciencedirect.com/science/ar…
Pleased to share the our work has been accepted for the upcoming #ACC26 ! See you all in NOLA! 🫀
@ACCinTouch @JACCJournals
1
13
584
Any place would be lucky to have you!🌟 🌟 🐐 🐐
This Post is from an account that no longer exists. Learn more
20
5,381
It was a pleasure attending and presenting our work at #AHA in Nola! I would like to thank all my co-authors for their efforts and my mentors @leonptaszek @JeremyRuskin for their continued support and guidance!
Always a pleasure to attend and present our work at TCT! 🫀
Thank you Dr. @AGoldsweig for your continued support and guidance!
#TCT2025
Thrilled to share our presentation has been accepted for the AHA 2025 Scientific Sessions!
Grateful to my mentors and colleagues for their support.
Looking forward to New Orleans this November!
#AHA25 #AHA2025 #MedTwitter #cardiotwitter
12
715
























